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Aim: Breast cancer (BC) is one of the most common forms of cancer amongst females. Early diagnosis, prognosis and therapy plays 
crucial role in the survival of patients with breast cancer. The study was aimed on identification of potential markers for early 
BC diagnostics by means of genome-wide comparative analysis of gene expression in cancer and normal tissue of breast. Methods: 
The analysis of gene expression in 15 invasive adenocarcinoma specimens and 15 normal breast tissue was conducted using the 
full-genome microarrays Sentrix HumanWD-6V3 BeadChip (Illumina). Methylation of TP53INK1 and TUSС5 promoters was 
interrogated by the combined bisulfite restriction analysis (COBRA). Results: Analysis of gene expression in the samples of breast 
adenocarcinoma revealed abnormal expression of more than 2,300 genes. While genes TFF1, S100P, ERBB2, TOP2A, CDF15, 
HOOK1, DNAJC12, CORO2A were up-regulated in cancer, decreased expression was found for genes TUSC5, SFRP1, PPPQR1B, 
NTRK4, TIMP4, BARD1, AKR1C2, TP53INK1 and others. Analysis of DNA methylation of TUSC5 by COBRA revealed higher 
levels of exon 1 methylation (11/12) in samples of breast cancer, whereas the gene was essentially unmethylated in matched normal 
appearing tissue of breast (2/12). TP53INK1 gene was methylated neither in cancer nor in normalcy. Conclusion: A total of 149 genes 
exhibited the highest difference in expression in cancer versus normal appearing tissue of breast. Most prominent down-regulated 
candidates, TUSC5 and TP53INK1, were reported for the first time in breast cancer and may be considered as potential markers 
of the disease. Aberrant DNA hypermethylation of TUSC5 suggests epigenetic mechanism of cancer associated down-regulation.
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The majority of breast cancer deaths are associ-
ated with metastases. Therefore, early detection 
of tumors would have substantial preventive effects. 
The routine diagnostic methods that are currently 
in use lack sensitivity for the detection of tumors at the 
early stage. For examples, mammography may lead 
to false-negative results in up to 31% of cases. Thus, 
identification of tumor-specific molecular markers 
is vital for development of new sensitive diagnostic 
methods that are capable of early detection of tumor 
cells [1]. Analysis of DNA methylation is one of the 
promising diagnostic approaches given the facts 
that: (1) aberrant DNA methylation occurs at any 
stage of tumorigenesis in various cancers including 
breast cancer [3]; (2) covalent cytosine modification 
by methylation is stable and can be readily detected 
in body ﬂuids; (3) modification of DNA by methylation 
is functionally involved in regulation of gene expression 
[2]. Cancer is associated with the global and localized 
hypermethylation of DNA in GC-rich regions referred 
to as CpG islands. Taken together, these properties 
of methylated DNA strongly suggest detection of DNA 
hypermethylation for cancer diagnostics. For instance, 
detection of hypermethylated promoters of certain 
genes has been suggested as potential clinical mark-
ers for early diagnostics of prostate cancer (GSTP1), 
prognosis of lung and colorectal cancer (p16INK4) and 
response to temozolomid treatment of glioma patients 
(MGMT) [4]. Therefore, identification of novel markers 
for early diagnostics, prognosis and therapy of breast 
cancer is of substantial practical use.
MATERIALS AND METHODS
Breast tissue samples. A total of 30 samples were 
analyzed in the study. These included 15 adenocarci-
nomas of breast along with matched normal-appearing 
breastspecimens. Fresh-frozen breast tissue samples 
were obtained, with written informed consent from 
patients from Odessa State Medical University after 
approval by the Institutional Review Board (Table 1).
RNA extraction and microarrray study. After 
surgical removal, samples were immediately placed 
in RNAlater Stabilization Reagent (Qiagen, Hilden, 
Germany), transported to the laboratory and frozen 
at -80 °C.  For RNA isolation, they were homogenized 
on dry ice using mortar and pestle. Total RNA was 
extracted using the RNEasy Mini Kit (Qiagen) accord-
ing to manufacturer’s instructions. The quality of iso-
lated patient RNA was controlled using a Bioanalyzer 
2100 (Agilent Technologies, Palo Alto, CA, USA). Full-
genome microarrays Sentrix HumanWD-6V3 BeadChip 
(Illumina inc., USA) were employed for analysis of gene 
expression. cDNA was synthesized using 1 µg of total 
RNA obtained from each tissue sample. Hybridisa-
tion to the BeadChip was performed according to the 
manufacturer’s instructions. A maximum of 10 µl cDNA 
was mixed with a 20 µL GEX-HYB hybridization solution. 
The preheated 30 µl assay sample was dispensed onto 
the large sample port of each array and incubated for 
18 hours at 58°C. Following hybridization, samples 
were washed according to the protocol and scanned 
with a BeadArray Reader (Illumina, San Diego, USA). 
Raw data were exported from the Beadstudio software 
to CHIPSTER software, whereby data quality assess-
ment, normalization and correspondence cluster 
analysis were performed. Most prominent candidate 
genes that were differentially expressed in cancer vs. 
normal-appearing tissue were identified by filtering 
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99.95% of all transcripts (р < 0.005). Pathway analy-
sis of the resulting genes was performed using IPA 
Ingenuity software.
DNA isolation, bisulfite conversion and com-
bined bisulfite restriction analysis (COBRA). 
Twelve samples of breast adenocarcinoma (10 ductal 
and 2 lobular forms) along with matched normal ap-
pearing tissue were used to analyze CpG methylation 
within exon 1 of TUSC5 and promoter of TP53INP1.
DNA was extracted by using QIAmp DNA Mini 
Kit and modified by sodium bisulfite with EpiTeсt 
Bisulfite kit of Qiagen. Interrogated DNA regions 
were amplified by PCR by using following primers: 
TUSC5-forward ATTAGTAAAGTTGTTT, TUSC5-
reverse CAAAAAACTCTAAAAAAA; TP53INP1-for-
ward1 ATTTTGGAGAGGGAATA, TP53INP1-re-
verse1 AAAAACTACTATCTTCCCCACCTC; TP53INP1-
for ward2 TTTAATTGTTTTTTTTGGTTAGTTTT, 
TP53INP1-reverse2 ATCCAACCATCACCT-ATA-
AATCC. Primers were designed by using Methyl Primer 
Express v. 1.0 (Applied Biosystems, USA). EpiTect 
control DNA set (Qiagen) was employed as a reference 
for totally methylated and unmethylated DNA samples. 
Amplicons were next incubated with BstUI restriction 
enzyme (New England Biolabs, USA) as suggested 
by the manufacturer and analyzed by electropho-
resis in 2%-agarose gel. Semiquantitative analysis 
of TUSC5 and TP53INP1 DNA methylation was per-
formed using the Quantity One software (Bio-Rad, 
USA) as earlier reported [5]. Methylation degree was 
estimated according to the equation
 CM = ————•100, 
 B + C
where B and C are amounts of unmethylated and 
methylated alleles, respectively.
RESULTS AND DISCUSSION
In this study, we aimed at identification of differ-
entially expressed genes in tumors of breast versus 
normal appearing breast tissue. To this end, genome-
wide gene expression profiling was performed (Fig.1). 
A total of 2300 genes were shown to be deregulated 
including 759 candidates with log fold change > 2.0. 
These included DNAJC12, TOP2A, STAT1, KIAA0101, 
GGT6, HOOK1, FLJ2315, TTF1, FSIP1, S100P, CRB14, 
GDF15, RASEF, TP531NP1, SEC14L2, TMEM26, 
MUC1, SUSD3, SPP1 etc. Significant down-regulation 
was shown for 73 genes: TUSC5, TP53INP1, CIDEC, 
CIDEA, SFRP1, GSTT1, DNAJC12, SOCS2, AQ7, HBB, 
IGSF1, GPD1, LEP, LPL, AKR1C2, CASP4, NTRK2, 
PPP1R1B, HOXA5, RBP4 etc. Significant up-regulated 
candidates included 76 genes: S100P, TFF1, CORO2A, 
FLG2351, C10orf106, C15orf48, VANGL2, UGT2B7, 
SOCS2, SUSD and others. Deregulation of the fol-
lowing genes in breast adenocarcinoma was reported 
for the first time: TUSC5, AQ7, CORO2A, FLJ2351, CI-
DEA, CIDEC, FAM89A, DDIT4L, C10orf106, C15orf48, 
MRAP, UGT2B7, CCDC3 and VANGL2.
Breast tumor sample Normal tissue
Fig. 1. Unsupervised clustering of gene expression data (rows) for 
breast cancer samples (columns at the left) and matched normal 
appearing tissue (columns at the right). In the heatmap, up-
regulation is shown in red, down-regulation is designated in green.
TP53INP1 and TUSC5 were among most promi-
nent down-regulated candidates in breast adeno-
carcinoma. TP53INP1 is stress-inducible protein that 
is responsible for phosphorylation of р53 in response 
to double-strand DNA breaks. TUSC5 is a presumable 
tumor suppressor. However, it function is poorly under-
stood. Given the fact that aberrant DNA hypermethyl-
ation is a frequent epigenetic event in cancer that is as-
sociated with loss of gene function, we hypothesized 
that TP53INP1 and TUSC5 may be epigenetically 
silenced. We addressed methylation of CGCG sites 
in exon 1 of TUSC5 and promoter of TP53INP1 by com-
bined bisulfite restriction analysis. Hypermethyl-
ation of CGCG site in TUSC5 was detected in 11 out 
of 12 samples of breast cancer with mean 51.4±3.1% 
methylation. Significantly lower methylation load was 
observed in normal appearing breast tissue of same 
patients (30.5±1.9%, p<0.002, Fig.2). TUSC5 meth-
ylation in two normal samples was higher (43% and 
41%) that in the rest of normal specimens, what may 
be explained by contamination of these samples with 
tumor cells (Table 2). These findings suggest epi-
genetic mechanism of TUSC5 deregulation. No DNA 
methylation was detected in TP53INP1 promoter both 
in cancer and normalcy suggesting an alternative 
mechanism of its deregulation
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Fig. 2. Comparison of TUSC5 gene methylation status in breast 
cancer and normal tissue in the same patients.
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Table. Methylation level of TUSC5 in brest cancer and matched normal 
appearing tissue
Sample ID Percent DNA methylationBreast cancer Normal appearing breast tissue
1 67 28
2 45 29
3 65 31
4 48 24
5 51 32
6 56 45
7 51 23
8 49 24
9 24 41
10 53 34
11 51 27
12 53 28
51.4 ± 3.1 30.5 ± 1.9 p = 0.0029
Our results are concordant with a report by Weng 
et al. [6], who have shown loss of TP53INP1 expres-
sion in esophageal carcinoma. However, in contrast 
to other malignancies, where TP53INP1 was shown 
(e.g., esophagus cancer and melanoma [7]), methyla-
tion could not be detected in our samples.
In conclusion.  a total of 149 genes exhibited the high-
est difference in expression in cancer versus normal ap-
pearing tissue of breast. Most prominent down-regulated 
candidates, TUSC5 and TP53INK1, were reported for 
the first time in breast cancer and may be considered 
as potential markers of the disease. Aberrant DNA hyper-
methylation of TUSC5 suggests epigenetic mechanism 
of cancer associated down-regulation.
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